secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0000950170-25-027336
Event type: earnings
Sentiment:  neutral
Materiality: 0.72
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam reports FY2024 net loss $241.6M, cash $834M; EMA submission on track for 2H25
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities totaled $834.2M at Dec 31, 2024, up from $340.5M.
- Revenue of $45.6M (FY2023: $14.1M) driven by a clinical milestone and cost reimbursement.
- Net loss widened to $241.6M from $176.9M; R&D spend fell to $151.4M while SG&A rose to $70.4M.
- Phase 3 BROADWAY met primary endpoint with 33% LDL-C reduction; TANDEM FDC achieved 49% reduction; BROOKLYN showed 36% reduction.
- EMA submission planned for 2H25 via partner Menarini; USPTO issued obicetrapib solid-form patent until July 2043.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000095017025027336/0000950170-25-027336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000095017025027336/nams-20250226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-027336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer